caplacizumab

Ligand id: 9123

Name: caplacizumab

Classification
Compound class Antibody
International Nonproprietary Names
INN number INN
9511 caplacizumab
Synonyms
ALX-0081
anti-vWF Nanobody
Database Links
Specialist databases
IMGT/mAb-DB 401
Other databases
Search PubMed clinical trials caplacizumab
Search PubMed titles caplacizumab
Search PubMed titles/abstracts caplacizumab
Comments
Caplacizumab (ALX-0081) is an investigational nanobody targeting von Willebrand factor (vWF) [4], with potential anti-thrombotic action [1]. NanobodyTM technology was commercially developed by Ablynx. Nanobodies are antibody derivatives comprising only the single variable domains (variable heavy, VH) whilst retaining full antigen binding capacity. Their relatively small size (compared to complete antibodies) provides the potential for alternative modes of delivery and the possibility of brain penetrance.
Annotated peptide sequences for this therapeutuc are available from its IMGT/mAb-DB record. BLAST protein sequence analysis of the peptide sequence submitted with the INN document for caplacizumab reveals a 100% match with SEQ ID NO: 90 claimed in patent US7807162 [3], which is preferred humanized variant 12A2H1 in the patent document.